Kotake T, Miki T, Akaza H, Kubota Y, Nishio Y, Matsumura Y, Ota K, Ogawa N
Department of Urology, Center for Adult Diseases, Osaka, Japan.
Cancer Chemother Pharmacol. 1991;27(4):253-7. doi: 10.1007/BF00685108.
The effects of recombinant granulocyte colony-stimulating factor (rG-CSF) on the myelosuppression, especially neutropenia, induced by cancer chemotherapy in patients with urogenital cancer were investigated in a randomized, controlled clinical study. In this study, rG-CSF was given subcutaneously at a dose of 2 micrograms/kg per day for 14 consecutive days. Changes in neutrophil counts were compared between the first (no rG-CSF) and second cycles (rG-CSF treatment period) of chemotherapy. rG-CSF administration was found to be effective in reducing the duration of neutropenia, in elevating the neutrophil nadir, and in reducing recovery time. Based on comparisons between the randomized rG-CSF treatment group (with rG-CSF) and the control group, treatment with rG-CSF resulted in the moderation or prevention of neutropenia and the acceleration of recovery. These results demonstrate that in chemotherapy of patients with urogenital cancer, in which neutropenia is a dose- or schedule-limiting factor, the concomitant use of rG-CSF may enable an increase in the dose (higher single dose or increased dose per unit of time) or shorten the chemotherapy period.
在一项随机对照临床研究中，研究了重组粒细胞集落刺激因子（rG-CSF）对泌尿生殖系统癌症患者因癌症化疗所致骨髓抑制尤其是中性粒细胞减少的影响。在本研究中，rG-CSF以每日2微克/千克的剂量皮下注射，连续注射14天。比较了化疗第一个周期（未使用rG-CSF）和第二个周期（rG-CSF治疗期）中性粒细胞计数的变化。结果发现，给予rG-CSF可有效缩短中性粒细胞减少的持续时间、提高中性粒细胞最低点计数并缩短恢复时间。基于随机rG-CSF治疗组（使用rG-CSF）与对照组之间的比较，使用rG-CSF治疗可减轻或预防中性粒细胞减少并加速恢复。这些结果表明，在以中性粒细胞减少作为剂量或疗程限制因素的泌尿生殖系统癌症患者化疗中，联合使用rG-CSF可能使剂量增加（单次更高剂量或单位时间内增加剂量）或缩短化疗周期。
